Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vk5211. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vk5211 SCHEMBL220947 | 1.00 | AR (1.00) | AR | |
| Vk5211 SCHEMBL14837444 | 1.00 | AR (1.00) | AR | |
| Vk5211 SCHEMBL221159 | 1.00 | AR (1.00) | AR | |
| Vk5211 SCHEMBL29362482 | 1.00 | AR (1.00) | AR | |
| Vk5211 SCHEMBL221160 | 1.00 | AR (1.00) | AR | |
| SCHEMBL224988 | 0.87 | AR (0.77) | AR | |
| SCHEMBL224989 | 0.87 | AR (0.77) | AR | |
| SCHEMBL20702204 | 0.87 | AR (0.77) | AR | |
| SCHEMBL2912623 | 0.87 | AR (0.77) | AR | |
| SCHEMBL223026 | 0.86 | AR (0.76) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104188971-B | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | 配体药物公司 | 2017-05-03 | — | — | CN | claimed |
| CN-104188971-A | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARM INC | 2014-12-10 | — | — | CN | claimed |
| CN-101945853-B | Selective androgen receptor modulators (sarms) and uses thereof | LIGAND PHARM INC | 2014-08-20 | — | — | CN | claimed |
| CN-101945853-A | Selective androgen receptor modulators (sarms) and uses thereof | LIGAND PHARM INC | 2011-01-12 | — | — | CN | claimed |
| WO-2024046605-A1 | COMPOUNDS FOR THE DETECTION OF LIGANDROL | NATIONAL CENTER FOR SCIENTIFIC RESEARCH "DEMOKRITOS" (GR) | 2024-03-07 | — | — | WO | disclosed |
| US-20220204448-A1 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | LIGAND PHARMACEUTICALS INC. | 2022-06-30 | — | — | US | disclosed |
| US-11040044-B2 | Methods of reducing mammographic breast density and/or breast cancer risk | Havah Therapeutics Pty Ltd. | 2021-06-22 | — | — | US | disclosed |
| WO-2020214834-A1 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | LIGAND PHARMACEUTICALS INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200253984-A1 | Methods of Reducing Mammographic Breast Density and/or Breast Cancer Risk | Havah Therapeutics Pty Ltd. (AU) | 2020-08-13 | — | — | US | disclosed |
| US-10471073-B2 | Methods of reducing mammographic breast density and/or breast cancer risk | Havah Therapeutics Pty Ltd. (AU) | 2019-11-12 | — | — | US | disclosed |
| US-20170319597-A1 | Methods of Reducing Mammographic Breast Density and/or Breast Cancer Risk | CHAVAH PTY LTD. (AU) | 2017-11-09 | — | — | US | disclosed |
| CN-104188971-B | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | 配体药物公司 | 2017-05-03 | — | — | CN | disclosed |
| CN-104188971-A | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARM INC | 2014-12-10 | — | — | CN | disclosed |
| CN-101945853-B | Selective androgen receptor modulators (sarms) and uses thereof | LIGAND PHARM INC | 2014-08-20 | — | — | CN | disclosed |
| US-8354446-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2012-01-05 | — | — | US | disclosed |
| CN-101945853-A | Selective androgen receptor modulators (sarms) and uses thereof | LIGAND PHARM INC | 2011-01-12 | — | — | CN | disclosed |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204448-A1 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | RCC1, CYP2F1, CENPE | AR 2451/4885 |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885 |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.